Tranilast (RIZABEN) is an old antiallergic drug, it is sold in Japan by KISSEY Pharmaceutical company for the treatment of allergies and also hypertrophic scar formation. Nuon Pharmaceuticals (San Mateo,CA) is developing it for new indications, including gout, rheumatoid arthritis and MS. Considerable amount of information on its pharmacology is available. Tranilast has been found to inhibit collagen synthesis in fibroblasts, decrease production of IL-6 and IL-8, inhibit VEGF-induced proliferation and migration of vascular endothelial cells, and to bind to aryl hydrocarbon receptors. These and other findings suggest that tranilast could be useful in the treatment of pulmonary fibrosis. Unfortunately, no clinical studies
in this indication are available or even planned.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment